Bio-Techne and Cell Signalling Technology Announce Partnership
Wednesday, February 15, 2023
Bio-Techne Corporation and Cell Signalling Technology (CST) announced the addition of Simple Western™ validation to CST antibodies. This will allow researchers in various disciplines an easier way to study important molecular signalling pathways on a trusted and validated platform. Obtaining accurate data efficiently and fast is key to advancing drug discovery and development.
This ongoing partnership will allow for an expanded menu of Simple Western validated antibodies for various targets across multiple disciplines.
This partnership with Cell Signalling Technology combines the strengths of the respective companies to provide researchers with new, more quantitative ways to interrogate signalling pathways. The assay optimisation efforts completed for this additional antibody catalogue will help scientists get groundbreaking results even faster.
